Commentary|Podcasts|November 4, 2025
Streamlining Clinical Data to Reduce Site and Participant Burden
Author(s)Andy Studna, Senior Editor
In this episode of the ACT Podcast, Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss the findings from a recent TransCelerate and Tufts CSDD study revealing that nearly one-third of data collected in Phase III trials is non-essential. They explore why trial complexity continues to grow despite industry efforts toward efficiency and share strategies for reducing data burden while maintaining compliance.
Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and TransCelerate program lead at Merck, discuss:
- Why clinical trial protocols continue to grow more complex despite efficiency initiatives
- Practical steps to streamline data collection while meeting regulatory expectations
- How sponsors, CROs, and sites can better collaborate on smarter data strategies to reduce burden and improve trial outcomes
- And more!
Related Content
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development
3
Before Burden Becomes Risk: Capturing Friction in Real Time
4
ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy
5